Celldex Therapeutics
CLDX Mid CapHealthcare · Biotechnology
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Celldex Therapeutics en bref
Celldex Therapeutics (CLDX) is currently trading at 28,30 € with a market capitalization of 2,2 Md €. The 52-week range spans from 17,03 € to 31,23 €; the current price is 9.4% below the yearly high. Year-over-year revenue growth stands at -97.8%.
💰 Dividende
Celldex Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
15 analystes évaluent Celldex Therapeutics (CLDX) au consensus : Achat Fort. L'objectif de cours moyen est de 50,21 €, soit un potentiel de +77.41% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 33,16 € à 78,54 €.
Celldex Therapeutics : la thèse d'investissement en détail
Celldex Therapeutics (CLDX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Wall Street consensus sits at Strong Buy with an average price target implying roughly 77.41% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Revenue is contracting at -97.8% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Short interest sits at 10.8% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
À surveiller
- The analyst consensus price target implies 77.41% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Consensus des analystes : Strong Buy
- Bilan solide avec faible endettement (D/E 0.42)
- –CA en contraction (-97.8% sur un an)
- –Positions vendeuses élevées (10.8%)
- –Free cash flow négatif
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (10.8%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Celldex Therapeutics?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
